Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/18: Can the Fed Afford to Keep the Suspense?
- PFP 6/18: Wednesday Fed Watch
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/18/2013
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
| ERICKSON AIR | EAC | 5.10% |
| ASSURED GUAR | AGO | 4.98% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
West Pharmaceutical Services (WST - Snapshot Report) recently announced the commercial launch of its B.safe syringe safety system. The company will employ its scalable technology for mass production to meet market demand in the first half of 2013.
West acquired the intellectual property rights to B.safe in 2011 and completed all phases of product development as well as the first stage of commercial scale-up at its manufacturing center for safety systems in France. The latest announcement reflects the company’s commitment to meet the increasing market demand for safety systems.
Per management, the market launch of B.safe marks a keystone in West’s operations. This newest offering will enhance the company’s portfolio and allow it to extend its foothold in the prefilled syringes and needle safety arena as the B.safe system is better designed to safeguard against needlestick injury, compared with other prefilled syringes.
In another story, West inked an agreement with Janssen Biotech, Inc. to develop and manufacture a leading-edge self-injection product aptly named SelfDose. The collaboration will enable the company to enhance its existing portfolio of self-injection technology as SelfDose complements West’s ConfiDose and SmartDose injection technologies.
The market introduction of B.safe along with the commercialization of SeflDose is expected to bolster the sales of the company’s Delivery Systems segment. It is also expected to boost the segment market share, which is currently lower than 5% of the total global market. Since the company’s financial metrics rely on revenues generated by injectable drugs, the launch of B.safe is expected to reinforce its performance.
West is a global leader in provision of drug administration systems and components for packaging, as well as delivery of injectable drugs and delivery system components across various industries.
The company has a significant competitive advantage in the market it serves. Additionally, it continues to make headway into new geographies to expand its business. However, macroeconomic pressure across the globe remains a headwind.
West, which competes with 3M Co. (MMM - Analyst Report) and Rexam plc. (REXMY) in certain niches, currently has a Zacks#2 Rank, which translates into a short-term Buy rating.
Get the full Analyst Report on MMM - FREE
Get the full on REXMY - FREE
Get the full Snapshot Report on WST - FREE